header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

144 PERIPROSTHETIC FEMORAL FRACTURES: MANAGEMENT AND OUTCOME



Abstract

Objectives: Retrospective case control study of management and outcome of periprosthetic femoral fractures, from the lower limb reconstruction unit in Exeter.

Material and Methods: 144 fractures over a period of 20 years were reviewed. The Vancouver classification system wasd used to clasify the fractures. The prosthesis length was measured pre and post-peratively. The use of impaction grafting technique for inadequate bone quality of the surrounding bone was assessed (type B3 fractures). The use of Dall/Miles, DCP and Mennen plates was also assessed. Healing was defined using radiological and clinical criteria and where available the Harris Hip Score. Chi-square test with p< 0.05 was used for the statistical analysis of the Results:

Results: When the Vancouver system was applied 2.85% of the fractures were classified as type A, 87.2% as type B and 10% as type C. Within the type B group 13.2% were subtype B1, 12% subtype B2 and 62% subtype B3. 1 out of 6 Mennen, 4 out of 16 Dall/Miles and 2 out of 20 DCP plates failed. Overall 68% healing, 5% non-union, 4% infection, 23% re-fracture rate at 12 months follow-up. Better healing was achieved when impaction grafting was used for B3 fractures (p=0.001). Better healing was achieved when the revision stem was bypassing the most distal fracture line by at least 2 ipsilateral femoral diameters and impaction grafting was used for B3 fractuires (p=0.01).

Conclusion: Impaction Grafting can compensate for the inadequate bone in type B3 fractures and appears to promote union. Revision stem should bypass the most distal fracture line by at least 2 cortical diameters to achieve healing.

Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland